SynthesisBMJ open2022
Quality of life in patients with breast cancer with neoadjuvant chemotherapy: a systematic review.
Synthesis in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Curative effect of immediate reconstruction after neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Psychological distress and coping strategies in breast cancer patients under neoadjuvant therapy: A systematic review.Women's health (London, England)Pooled it
- Trial
- Exploring the feasibility of exercise training during (neo)adjuvant chemotherapy in women with early-stage breast cancer: a pilot study examining immune and metabolic outcomes.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Quality of life and psychological outcomes with albumin-bound paclitaxel-carboplatin versus solvent-based paclitaxel-carboplatin as first-line chemotherapy in stage IC-IV ovarian carcinoma.Gynecologic oncology reports · 2026Article
- The Impact of Time and Place on BREAST-Q REACT: A Multi-Institutional Examination.Journal of surgical oncology · 2026Article
- Dynamic trajectories of health-related quality of life during neoadjuvant chemotherapy in breast cancer: differential effects of anthracycline-taxane sequencing.Science China. Life sciences · 2026Article
- Article
- Evaluation of the Quality of Life of Women with Breast Cancer in Morocco.Annals of African medicine · 2026Article
- Outcomes of a prospective cohort study of PREoperative therapy and supportive care in early & locally advanced breast cancers-PreSCella study.NPJ breast cancer · 2026Article
- Connotation and Mechanism of Family Support for Patients with Chronic Diseases Under the Perspective of Health Promotion-A Scoping Review of Reviews.Journal of multidisciplinary healthcare · 2026Review
- Prehabilitation for patients undergoing neoadjuvant treatment: results of a single-center pilot study using an integrative medicine day clinic.Frontiers in oncology · 2026Article
- Subtype-specific health and economic impact of delayed breast cancer diagnosis during the early COVID-19 pandemic in Belgium: a Markov model analysis.Breast cancer research : BCR · 2025Article
- Eye Movement Impairment in Women Undergoing Chemotherapy.Journal of eye movement research · 2025Article
- The Mediating Role of Early Maladaptive Schemas in the Relationship Between Attachment Styles and Adjustment to Early-Stage Breast Cancer.Psycho-oncology · 2025Article
- SNP's use as a potential chemotoxicity stratification tool in breast cancer: from bench to clinic.Functional & integrative genomics · 2025Review
- Pharmacogenetics as a Future Tool to Risk-Stratify Breast Cancer Patients According to Chemotoxicity Potential from the Doxorubicin Hydrochloride and Cyclophosphamide (AC) Regimen.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Hepatocellular Carcinoma and Health-Related Quality of Life: A Systematic Review of Outcomes From Systemic Therapies.International journal of hepatology · 2025Article
- Dkk1 as a Prognostic Marker for Neoadjuvant Chemotherapy Response in Breast Cancer Patients.Cancers · 2024Article
- Predictors of recurrence in breast cancer patients with pathological partial response.Revista da Associacao Medica Brasileira (1992) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe aims of this systematic review were to assess the impact of neoadjuvant chemotherapy (NAC) on breast cancer (BC) patients' quality of life (QOL), to compare the different regimens of NAC on BC patients' QOL, to compare NAC versus adjuvant chemotherapy on BC patients' QOL and to identify predictors of QOL on patients with BC receiving NAC.
designThe design used Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. DATA SOURCES: Cinahl, Embase, Pubmed, Scopus, Web of Science, Cochrane library and PsycINFO were searched through 27 December 2021. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: The inclusion criteria were included: patients with BC receiving NAC, outcome measures related to QOL and published in English. The exclusion criteria were included: duplicates or overlapping participants, not original research, data or full text not available and qualitative study. DATA EXTRACTION AND SYNTHESIS: Two independent reviewers used standardised methods to search, screen and code included studies. The risk of bias in individual studies was evaluated with Cochrane collaboration's tool for assessing risk bias, Newcastle Ottawa Score or Joanna Briggs Institute Critical Appraisal tool. This systematic review performs narrative synthesis based on several different themes.
resultsThe initial search resulted in 2994 studies; 12 of these studies fulfilled inclusion criteria. There was no significant difference in the QOL of BC before and after NAC, but patients experienced adverse reactions and depression during chemotherapy. Different regimens of NAC have different effects on patients' QOL. Patients with NAC had more severe physical discomfort than those with adjuvant chemotherapy. However, BC patients' QOL can be improved by intervening on social or family support, and these predictors, including chronotype, QOL before NAC and depression.
conclusionsMore original research is needed in future to understand the profile and predictors of QOL in patients with BC on NAC, which will help clinicians and patients make decisions and deal with NAC-related issues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.